N. LammozaAlfred Health, Melbourne, AustraliaA. AungAlfred Health, Melbourne, AustraliaA. ThayaparanAlfred Health, Melbourne, AustraliaS. VasudevanAustin Health, Melbourne, Vic, AustraliaG. EdwardsAlfred Health, Melbourne, AustraliaM. HomizAustin Health, Melbourne, Vic, AustraliaH. Gibbs...
SGLT2 inhibitors reduce the risk of anaemia and hyperkalaemia, which are common complications in patients with CKD or heart failure. The characteristic decline in estimated glomerular filtration rate after initiation of SGLT2 inhibitors reflects their renal haemodynamic effects and is not associated with...
These in vitro findings suggest that SGLT2 inhibitors may provide renoprotection in diabetes by avert- ing glucose from entering proximal tubule cells20,21. However, in recent preclinical studies, renoprotection with SGLT2 inhibition has been seen only when blood glucose levels were markedly improved...
Second, SGLT2 inhibitors may increase myocardial energy production; alleviate systemic microvascular dysfunction, which is prevalent in both the myocardium and skeletal muscle in HFpEF; improve systemic endothelial function; reduce systemic inflammation and oxidative stress; and improve insulin sensitivity and...
Long-term clinical studies on the incidence of microvascular complications, such as diabetic nephropathy, are ongoing and will determine whether SGLT2 inhibitors exert benefits that are superior to traditional agents13. While we were unable to show considerable improvements in renal function, the ...
According to post-marketing surveillance of SGLT2 inhibitors, infections, pruritus, photosensitivity, and urticaria topped the reported list of 1136 cases of skin and subcutaneous tissue adverse drug reactions [65]. Mellander et al. [67] reported hypersensitivity-related cutaneous adverse events ...
SGLT2 inhibitors;cutaneous adverse drug reactions;diabetes mellitus;antidiabetics;oral hypoglycemic agents;diabetes mellitus 1. Introduction Type 2 diabetes mellitus (T2DM) is a global health issue with an estimated global prevalence of 463 million people, with its incidence on the rise along with mul...